These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24023346)

  • 1. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
    Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
    Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
    Coskun U; Buyukberber S; Yaman E; Uner A; Er O; Ozkan M; Dikilitas M; Oguz M; Yildiz R; B DY; Kaya AO; Benekli M
    Neoplasma; 2008; 55(1):65-70. PubMed ID: 18190244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
    Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
    Leone F; Artale S; Marino D; Cagnazzo C; Cascinu S; Pinto C; Fornarini G; Tampellini M; Di Fabio F; Sartore-Bianchi A; De Carlis L; Pugliese R; Capussotti L; Gioeni L; Siena S; Aglietta M
    Cancer; 2013 Oct; 119(19):3429-35. PubMed ID: 23868516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
    Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
    BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
    J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
    Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
    Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
    Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
    J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
    Comella P; Massidda B; Palmeri S; Farris A; Lucia LD; Natale D; Maiorino L; Tafuto S; Cataldis GD; Casaretti R
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):481-6. PubMed ID: 15902461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
    Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
    Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Alberts SR; Horvath WL; Sternfeld WC; Goldberg RM; Mahoney MR; Dakhil SR; Levitt R; Rowland K; Nair S; Sargent DJ; Donohue JH
    J Clin Oncol; 2005 Dec; 23(36):9243-9. PubMed ID: 16230673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.